Bharat Biotech International Limited on Monday announced that its COVID-19 intranasal vaccine iNCOVACC (BBV154) has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.
A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.
The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops, it said. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, Bharat Biotech said.
The vaccine had earlier received approval under Restricted Use in Emergency Situation for ages 18 and above for primary two-dose schedule. Phase-III trials were conducted for safety, immunogenicity in approximately 3,100 subjects, at 14 trial sites across India.
Krishna Ella, Chairman & Managing Director, Bharat Biotech, said: "Despite the lack of demand for COVID vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases… We have also initiated development of variant-specific vaccines for COVID for future preparedness."
iNCOVACC was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.
Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said, "The DCGI’s approval of Bharat Biotech’s intranasal vaccine iNCOVACC (BBV154) to be used as a heterologous booster dose against currently available COVID-19 vaccines is a moment of great pride for our country. This move will further strengthen our collective fight against the pandemic and broaden vaccine coverage."
Also read: Cyrus Poonwalla turns 4th richest Indian, thanks to bumper profits from Covid-19 vaccines
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Lok Sabha elections 2024: What's the vote-from-home facility? Know eligibility and procedure
Mar 28, 2024 4:02 PM
Poll officers cannot force electors who 'refuse' to vote at polling booths, says EC rule
Mar 28, 2024 2:19 PM
'Committed to serving you as son': Varun Gandhi's note for people of Pilibhit after BJP denies him ticket
Mar 28, 2024 2:03 PM
Lok Sabha elections 2024: Raigarh to Bastar, key seats in Chhattisgarh
Mar 28, 2024 11:40 AM